Elinogrel

DB06350InvestigationalSmall molecule

A P2Y12 inhibitor and platelet aggregation inhibitor.

Mechanism: PRT060128 is a specific, reversible ADP receptor antagonist that binds to the P2Y12 receptor on platelets. PRT06128 prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, a key step in the coagulation cascade. PRT060128 likely has a similar mechanism of action to clopidogrel.
Curator reviewed
Primary indication: Investigated for use/treatment in cardiovascular disorders and myocardial infarction.Curator reviewed
Formula / weight: C₂₀H₁₅ClFN₅O₅S₂ · 523.94 g/mol (avg)
Code names: PRT-060128

Resolves to

Compound

Structure

InChIKeyLGSDFTPAICUONK-UHFFFAOYSA-NSMILESCNC1=C(F)C=C2C(NC(=O)N(C2=O)C2=CC=C(NC(=O)NS(=O)(=O)C3=CC=C(Cl)S3)C=C2)=C1

Targets

What you can answer from here — as of September 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elinogrel, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.